 DUBLIN, June 4, 2021 PRNewswire -- Alkermes plc Nasdaq: ALKS today announced new data from its ARTISTRY clinical development program for nemvaleukin alfa nemvaleukin, Alkermes novel, investigational engineered interleukin-2 IL-2 variant immunotherapy. The data are being presented at the 2021 American Society of Clinical Oncology ASCO Annual Meeting, taking place virtually June 4-8, 2021, and in an investor webcast presentation hosted by the company. 